COVID-19 Update from FSSolutions

Due to the recent COVID-19 surge, some clinics and collection sites in our network are experiencing capacity and staffing issues. FSSolutions’ is doing its best to mitigate these issues, which may impact documentation and turnaround time. Please have your donors/candidates call the site to confirm hours of operation and wait time.

Breaking News – DTAB Recommendations Approved By HHS

We are very pleased to announce that yesterday, the Departmentof Health and Human Services (HHS), Substance Abuse and MentalHealth Services Administration (SAMHSA) Administrator – Pamela S.Hyde, J.D. – approved [see attachment] both of the Drug TestingAdvisory Board (DTAB) July, 2011, recommendations:

  • Based on review of the science, DTAB recommends that SAMHSAinclude oral fluid as an alternative specimen in the MandatoryGuidelines for Federal Workplace Drug Testing Programs. 
  • DTAB recommends the inclusion of additional Schedule IIprescription medications (e.g., oxycodone, oxymorphone, hydrocodoneand hydromorphone) in the Mandatory Guidelines for FederalWorkplace Drug Testing Programs.

We believe the opportunity to address the illicit use and abuseof these additional Schedule II drugs in the transportationindustries is an important way to limit their misuse in ourcommunities and a great way to serve transportation safety, whilegetting those who need treatment into treatment.  And pleaseknow that oral fluid testing will be a bonus to our regulatedtransportation industry program; and will certainly serve to assistthe  DOT’s National Highway Traffic Safety Administration inits efforts, with others, to establish national per se laws forDriving Under the Influence of Drugs (DUID).

As you know, the DOT is required by law to follow HHS proceduresfor the drugs for which we test and the specimens we test. Therefore, we will continue to work with the DTAB, HHS/SAHMSA, theOffice of National Drug Control Policy, and others to bring theseapproved recommendations to realization in our regulations andthroughout the transportation industries.

Sincerely,

Jim L. Swart
Director
Office of Drug and Alcohol Policy and Compliance
Office of the Secretary of Transportation
U.S. Department of Transportation

See All News & Events